Clinical Trials Browser

Recruiting × Hematologic Neoplasms × ivosidenib × Clear all

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 1 Recruiting

291 enrolled 3 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms